


What is claimed is:

1. A compound of Formula I or a pharmaceutically acceptable salt thereof:



I

5 wherein

R¹ is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, C₄₋₈cycloalkenyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, and C₃₋₆heterocycloalkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, C₄₋₈cycloalkenyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, 10 C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, and C₃₋₆heterocycloalkyl used in defining R¹ is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C₁₋₆alkylamino and diC₁₋₆alkylamino;

R² is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, and C₄₋₈cycloalkenyl-C₁₋₄alkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, and C₄₋₈cycloalkenyl-C₁₋₄alkyl used in defining R² is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C₁₋₆alkylamino and diC₁₋₆alkylamino;

R³ is selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl, and C₁₋₆acyl, wherein said C₁₋₆alkyl, C₂₋₆alkenyl, and C₁₋₆acyl used in defining R³ is optionally substituted with one or more groups selected from CH₃C(=O)-O-, halogen, cyano, methoxy, ethoxy, hydroxy, amino, alkylamino, dialkylamino, and C₃₋₆heterocycloalkyl; and

R⁴ is selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, and C₃₋₆cycloalkyl-C₁₋₄alkyl.

2. A compound as claimed in claim 1, wherein

R¹ is selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, C₄₋₆cycloalkenyl-C₁₋₄alkyl and C₃₋₆heterocycloalkyl-C₁₋₄alkyl, wherein said C₁₋₆alkyl,

C_{2-6} alkenyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{4-6} cycloalkenyl- C_{1-4} alkyl and C_{3-6} heterocycloalkyl- C_{1-4} alkyl used in defining R^1 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, hydroxy and amino;

R^2 is selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, and C_{4-6} cycloalkenyl- C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, and C_{4-6} cycloalkenyl- C_{1-4} alkyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy and hydroxy;

R^3 is selected from -H, C_{1-6} alkyl, C_{2-6} alkenyl, and C_{1-6} acyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, and C_{1-6} acyl used in defining R^3 is optionally substituted with one or more groups selected from $CH_3C(=O)-O-$, halogen, methoxy, ethoxy, hydroxy, amino, methylamino, dimethylamino, and C_{3-6} heterocycloalkyl; and

R^4 is selected from -H and C_{1-3} alkyl.

15 3. A compound as claimed in claim 1,

R^1 is selected from cyclopentyl-methyl, cyclohexyl-methyl, cyclobutyl-methyl, cyclopropyl-methyl, 4,4-difluorocyclohexyl-methyl, bicyclo[2.2.1]hept-5-en-2-ylmethyl, tetrahydropyranyl-methyl, tetrahydropyranyl-ethyl, tetrahydrofuranyl-methyl, morpholinyl-methyl, piperdinylethyl, N-methyl-piperdinylmethyl, and piperdinylmethyl;

R^2 is selected from t-butyl, n-butyl, 2-methyl-2-butyl, isopentyl, 2-methoxy-2-propyl, 2-hydroxy-propyl, trifluoromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl, 1-methyl-propyl, 1,1-dimethyl-propyl, 1,1-dimethyl-3-buten-1-yl, ethyl, and 2-propyl;

R^3 is selected from -H, C_{1-6} alkyl, and C_{1-6} acyl, wherein said C_{1-6} alkyl, and C_{1-6} acyl used in defining R^3 is optionally substituted with one or more groups selected from $CH_3C(=O)-O-$, halogen, methoxy, hydroxy, amino, methylamino, dimethylamino, pyrrolidinyl, and morpholinyl; and

R^4 is selected from -H and methyl.

30 4. A compound as claimed in claim 1, wherein

R^1 is selected from cyclohexyl-methyl, cyclopentyl-methyl, cyclobutyl-methyl, cyclopropyl-methyl, 4,4-difluorocyclohexyl-methyl and tetrahydropyranyl-methyl;

R^2 is *t*-butyl and 1,1-difluoroethyl;

R^3 is selected from -H, methyl, ethyl, propyl, 2-propyl, 2-hydroxyethyl, 2-methoxyethyl, formyl, acetyl, ethylcarbonyl, 2-propylcarbonyl, *t*-butylcarbonyl, uriedo, N-isopropyl-ureido, 2-amino-acetyl, 2-methylamino-acetyl, 2-dimethylamino-acetyl, 2-acetyloxy-acetyl, 2-hydroxy-acetyl, 2-bromo-acetyl, 2-(morpholin-1-yl)-acetyl, and 2-(pyrrolindin-1-yl)-acetyl; and

R^4 is selected from -H and methyl.

5. A compound selected from:

10 N -(4-{[[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl) acetamide;
 N -[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methyl-4-nitrobenzenesulfonamide;
4-Amino- N -[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;

15 N -(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)propanamide;
 N -(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-methylpropanamide;

20 N -(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide;
 N -[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-(ethylamino)-*N*-methylbenzenesulfonamide;
25 N -[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-(formylamino)-*N*-methylbenzenesulfonamide;
 N -(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-pyrrolidin-1-ylacetamide;
 N^1 -(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)- N^2 , N^2 -dimethylglycinamide;

30 N -(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-morpholin-4-ylacetamide;
 N^1 -(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)glycinamide;

2-[(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)amino]-2-oxoethyl acetate;
N-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide;

5 5-Bromo-N-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-6-chloro-N-methylpyridine-3-sulfonamide;
5-Bromo-N-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-6-[(2-hydroxyethyl)amino]-N-methylpyridine-3-sulfonamide;

10 N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-6-[(2-hydroxyethyl)amino]-N-methylpyridine-3-sulfonamide;
N-(5-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}pyridin-2-yl)acetamide;

15 N-(3-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
N¹-(4-{[[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-N²-(2-hydroxyethyl)glycinamide;
4-[(Aminocarbonyl)amino]-N-[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-N-methylbenzenesulfonamide;

20 N-(4-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
N-(4-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-N-methylacetamide;

25 N-(4-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide;
N-(4-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide;

30 N¹-(4-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-N²,N²-dimethylglycinamide;
N¹-(4-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)glycinamide;
N¹-(4-{[[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-N²-methylglycinamide;


N-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-6-[(2-hydroxyethyl)amino]-*N*-methylpyridine-3-sulfonamide;
N-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-6-[(2-methoxyethyl)amino]-*N*-methylpyridine-3-sulfonamide;
5 *N*-[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-6-(formylamino)-*N*-methylpyridine-3-sulfonamide;
 N-(5-{{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl)pyridin-2-yl)acetamide;
 N-[4-{{[2-*tert*-Butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl]phenyl]acetamide;
10 *N*-[4-{{[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl]phenyl]acetamide;
 N-(4-{{[2-*tert*-Butyl-1-(2-piperidin-1-ylethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl)phenyl]acetamide;
15 *N*-(4-{{[2-*tert*-Butyl-1-(1,4-dioxan-2-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl)phenyl]acetamide;
 N-(4-{{[2-*tert*-Butyl-1-[(1-methylpiperidin-2-yl)methyl]-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl)phenyl]acetamide;
 N-(4-{{(2-*tert*-Butyl-1-[(2*R*)-1-methylpiperidin-2-yl]methyl)-1*H*-benzimidazol-5-yl}(methyl)amino)sulfonyl)phenyl]acetamide;
20 *N*-[4-{{methyl[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl]phenyl]acetamide;
 4-Bromo-*N*-[1-(cyclohexylmethyl)-2-(1,1-dimethylethyl)-1*H*-benzimidazol-5-yl]-*N*-methyl-benzenesulfonamide;
25 *N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-[(2-hydroxyethyl)amino]-*N*-methylbenzenesulfonamide;
 N-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-4-(dimethylamino)-*N*-methylbenzenesulfonamide;
 4-[bis(2-hydroxyethyl)amino]-*N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;
30 *N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*,4-dimethyl-3,4-dihydro-2*H*-1,4-benzoxazine-7-sulfonamide;

N-[4-({methyl[2-(1-methyl-1-pyridin-2-ylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;
N-(4-{[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](ethyl)amino}sulfonyl)phenyl]acetamide;
5 4-[(aminocarbonyl)amino]-*N*-[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-ethylbenzenesulfonamide;
N-[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-ethyl-4-{{(methylamino)carbonyl}amino}benzenesulfonamide;
10 4-amino-*N*-[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-ethylbenzenesulfonamide;
N-(4-{[[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](ethyl)amino}sulfonyl)phenyl)-2,2-dimethylpropanamide;
2-[(4-{{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](ethyl)amino}sulfonyl)phenyl]amino]-2-oxoethyl acetate;
15 *N*-(4-{{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](ethyl)amino}sulfonyl)phenyl)-2-hydroxyacetamide;
N-[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-ethyl-4-{{(isopropylamino)carbonyl}amino}benzenesulfonamide;
N-[4-({ethyl[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]acetamide;
20 4-[(aminocarbonyl)amino]-*N*-ethyl-*N*-[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
N-ethyl-*N*-[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-4-{{(methylamino)carbonyl}amino}benzenesulfonamide;
25 4-amino-*N*-ethyl-*N*-[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
N-[4-({ethyl[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]-2,2-dimethylpropanamide;
30 2-{{[4-({ethyl[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]amino}-2-oxoethyl acetate;
N-[4-({ethyl[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl)phenyl]-2-hydroxyacetamide;

N-ethyl-4-{{(isopropylamino)carbonyl]amino}-*N*-[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
N-(4-{{[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
5 4-[(aminocarbonyl)amino]-*N*-[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;
2-Hydroxy-*N*-(4-{{[2-(1-methoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
10 *N*-(4-{{[2-(1-ethoxy-1-methylethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
N-[4-{{[1-(2-azetidin-1-ylethyl)-2-*tert*-butyl-1*H*-benzimidazol-5-yl]amino]sulfonyl}phenyl]acetamide;
3-[5-{{[4-(acetylamino)phenyl]sulfonyl}amino}-2-*tert*-butyl-1*H*-benzimidazol-1-yl]propyl acetate;
15 *N*-{4-{{[1-[(1*S*,4*S*)-bicyclo[2.2.1]hept-5-en-2-ylmethyl]-2-*tert*-butyl-1*H*-benzimidazol-5-yl]amino]sulfonyl}phenyl]acetamide;
N-[4-{{[2-*tert*-butyl-1-(tetrahydro-2*H*-pyran-3-ylmethyl)-1*H*-benzimidazol-5-yl]amino]sulfonyl}phenyl]acetamide;
20 *N*-{4-{{[2-*tert*-butyl-1-[2-(tetrahydro-2*H*-pyran-4-yl)ethyl]-1*H*-benzimidazol-5-yl]amino]sulfonyl}phenyl]acetamide;
N-(4-{{[2-*tert*-butyl-1-(cyclobutylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
4-[(aminocarbonyl)amino]-*N*-[2-*tert*-butyl-1-(cyclobutylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;
25 *N*-(4-{{[2-*tert*-butyl-1-(cyclobutylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2,2-dimethylpropanamide;
N-(4-{{[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-2-hydroxyacetamide;
30 *N*-(4-{{[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide;
N-(4-{{[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)-3-methylbutanamide;

N-(4-{{[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl](methyl)amino}sulfonyl)phenyl)-2,2-dimethylpropanamide;
N-[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-4-{{(isopropylamino)carbonyl}amino}-*N*-methylbenzenesulfonamide;
5 4-{{Bis(isopropylamino)carbonyl}amino}-*N*-[2-(1,1-difluoroethyl)-1-(tetrahydro-2*H*-pyran-4-ylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylbenzenesulfonamide;
N-[4-{{methyl[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl]phenyl]acetamide;
4-{{(aminocarbonyl)amino}-*N*-methyl-*N*-[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-
10 (trifluoromethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
N-methyl-4-nitro-*N*-[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
4-amino-*N*-methyl-*N*-[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-
15 1*H*-benzimidazol-5-yl]benzenesulfonamide;
2,2-dimethyl-*N*-[4-{{methyl[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-
(trifluoromethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl]phenyl]propanamide;
2-{{[4-{{methyl[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl]phenyl}amino}-2-oxoethyl acetate;
4-{{(isopropylamino)carbonyl}amino}-*N*-methyl-*N*-[1-(tetrahydro-2*H*-pyran-4-
20 ylmethyl)-2-(trifluoromethyl)-1*H*-benzimidazol-5-yl]benzenesulfonamide;
2-Hydroxy-*N*-[4-{{methyl[1-(tetrahydro-2*H*-pyran-4-ylmethyl)-2-
(trifluoromethyl)-1*H*-benzimidazol-5-yl]amino}sulfonyl]phenyl]acetamide
and pharmaceutically acceptable salts thereof.

25 6. A compound of Formula IA, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:

IA

wherein

G is CH or N;

X¹ is halogen;

R¹ is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl,

5 C₄₋₈cycloalkenyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, and C₃₋₆heterocycloalkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, C₄₋₈cycloalkenyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, and C₃₋₆heterocycloalkyl used in defining R¹ is optionally substituted by one or more groups selected from halogen, cyano, nitro, 10 methoxy, ethoxy, methyl, ethyl, hydroxy, CH₃C(=O)-O-, amino, C₁₋₆alkylamino and diC₁₋₆alkylamino;

R² is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, and C₄₋₈cycloalkenyl-C₁₋₄alkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, and C₄₋₈cycloalkenyl-C₁₋₄alkyl used in

15 defining R² is optionally substituted by one or more groups selected from halogen, C₃₋₅heteroaryl, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C₁₋₆alkylamino and diC₁₋₆alkylamino;

R³ and R^{3a} are independently selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₃alkyl-O-C(=O)-, C₁₋₆alkyl-HN-C(=O)-, H₂N-C(=O)-, and C₁₋₆acyl, wherein said C₁₋₆alkyl, C₂₋₆alkenyl, and C₁₋₆acyl used in defining R³ is optionally substituted with one

20 or more groups selected from CH₃C(=O)-O-, halogen, cyano, methoxy, ethoxy, hydroxy, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, and C₃₋₆heterocycloalkyl; and

R⁴ is selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, and C₃₋₆cycloalkyl-C₁₋₄alkyl.

25

7. A compound as claimed in claim 6

wherein

G is CH or N;

R¹ is selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl-C₁₋₄alkyl,

30 C₄₋₆cycloalkenyl-C₁₋₄alkyl and C₃₋₆heterocycloalkyl-C₁₋₄alkyl, wherein said C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, C₄₋₆cycloalkenyl-C₁₋₄alkyl and C₃₋₆heterocycloalkyl-C₁₋₄alkyl used in defining R¹ is optionally substituted by one or

more groups selected from halogen, methoxy, ethoxy, methyl, hydroxy, $\text{CH}_3\text{C}(=\text{O})\text{-O-}$, amino, $\text{C}_{1-6}\text{alkylamino}$ and $\text{diC}_{1-6}\text{alkylamino}$;

5 R^2 is selected from $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{3-6}\text{cycloalkyl}$, $\text{C}_{3-6}\text{cycloalkyl-}\text{C}_{1-4}\text{alkyl}$, and $\text{C}_{4-6}\text{cycloalkenyl-}\text{C}_{1-4}\text{alkyl}$, wherein said $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{3-6}\text{cycloalkyl}$, $\text{C}_{3-6}\text{cycloalkyl-}\text{C}_{1-4}\text{alkyl}$, and $\text{C}_{4-6}\text{cycloalkenyl-}\text{C}_{1-4}\text{alkyl}$ used in defining R^2 is optionally substituted by one or more groups selected from halogen, $\text{C}_{3-5}\text{heteroaryl}$, methoxy, ethoxy and hydroxy;

10 R^3 is selected from $-\text{H}$, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{1-3}\text{alkyl-O-C}(=\text{O})\text{-}$, $\text{C}_{1-3}\text{alkyl-HN-C}(=\text{O})\text{-}$, $\text{H}_2\text{N-C}(=\text{O})\text{-}$, and $\text{C}_{1-6}\text{acyl}$, wherein said $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, and $\text{C}_{1-6}\text{acyl}$ used in defining R^3 is optionally substituted with one or more groups selected from $\text{CH}_3\text{C}(=\text{O})\text{-O-}$, halogen, methoxy, ethoxy, hydroxy, amino, methylamino, dimethylamino, and $\text{C}_{3-6}\text{heterocycloalkyl}$; and

15 R^4 is selected from $-\text{H}$ and $\text{C}_{1-3}\text{alkyl}$.

15 8. A compound as claimed in claim 6

wherein G is CH or N ;

20 R^1 is selected from cyclopentyl-methyl, cyclohexyl-methyl, cyclobutyl-methyl, cyclopropyl-methyl, 4,4-difluorocyclohexanemethyl, bicyclo[2.2.1]hept-5-en-2-ylmethyl, tetrahydropyranyl-methyl, tetrahydropyranyl-ethyl, tetrahydrofuranyl-methyl, morpholinyl-methyl, piperdinylethyl, N -methyl-piperdinylmethyl, and piperdinylmethyl;

25 R^2 is selected from t-butyl, n-butyl, 2-methyl-2-butyl, isopentyl, 2-methoxy-2-propyl, 2-hydroxy-propyl, trifluoromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl, 1-methyl-propyl, 1,1-dimethyl-propyl, 1,1-dimethyl-3-buten-1-yl, ethyl, and 2-propyl;

25 R^3 is selected from $-\text{H}$, $\text{C}_{1-6}\text{alkyl}$, and $\text{C}_{1-6}\text{acyl}$, wherein said $\text{C}_{1-6}\text{alkyl}$, and $\text{C}_{1-6}\text{acyl}$ used in defining R^3 is optionally substituted with one or more groups selected from $\text{CH}_3\text{C}(=\text{O})\text{-O-}$, halogen, methoxy, hydroxy, amino, methylamino, dimethylamino, pyrrolidinyl, piperidinyl and morpholinyl; and

30 R^4 is selected from $-\text{H}$ and methyl.

30

9. A compound as claimed in claim 6

wherein

G is CH or N ;

X¹ is bromo;


R¹ is cyclohexyl-methyl, cyclobutyl-methyl, 4,4-difluorocyclohexanemethyl, N-methylpiperidine-2-yl methyl, and tetrahydropyranyl-methyl;

R² is t-butyl and 1,1-difluoroethyl;

5 R³ is selected from -H, methyl, ethyl, propyl, 2-propyl, 2-hydroxyethyl, 2-methoxyethyl, formyl, acetyl, uriedo, N-isopropyl-ureido, ethylcarbonyl, 2-propylcarbonyl, t-butylcarbonyl, 2-amino-acetyl, 2-methylamino-acetyl, 2-dimethylamino-acetyl, 2-acetoxy-acetyl, 2-hydroxy-acetyl, 2-bromo-acetyl, 2-(morpholin-1-yl)-acetyl, and 2-(pyrrolindin-1-yl)-acetyl; and

10 R⁴ is selected from -H and methyl.

10. A compound of Formula IB, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:



15

IB

wherein

R¹ is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, C₄₋₈cycloalkenyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, and C₃₋₆heterocycloalkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, C₄₋₈cycloalkenyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, and C₃₋₆heterocycloalkyl used in defining R¹ is

20 optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C₁₋₆alkylamino and diC₁₋₆alkylamino;

25 R² is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, and C₄₋₈cycloalkenyl-C₁₋₄alkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, and C₄₋₈cycloalkenyl-C₁₋₄alkyl used in defining R² is optionally substituted by one or more groups selected from halogen,

methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C₁₋₆alkylamino and diC₁₋₆alkylamino;

"Het" is a nitrogen (as shown in Formula IB) containing heterocycle ring that is fused with phenyl ring "Ar," wherein "Het" is optionally substituted with one or more groups selected from C₁₋₃alkyl, halogen, cyano, methoxy, ethoxy, hydroxy, and amino; and

R⁴ is selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, and C₃₋₆cycloalkyl-C₁₋₄alkyl.

10 11. A compound as claimed in claim 10

wherein

R¹ is selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, C₄₋₆cycloalkenyl-C₁₋₄alkyl and C₃₋₆heterocycloalkyl-C₁₋₄alkyl, wherein said C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, C₄₋₆cycloalkenyl-C₁₋₄alkyl and C₃₋₆heterocycloalkyl-C₁₋₄alkyl used in defining R¹ is optionally substituted by one or

more groups selected from halogen, methoxy, ethoxy, methyl, hydroxy, amino, C₁₋₆alkylamino and diC₁₋₆alkylamino;

R² is selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, and C₄₋₆cycloalkenyl-C₁₋₄alkyl, wherein said C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, and C₄₋₆cycloalkenyl-C₁₋₄alkyl used in defining R² is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy and hydroxy;

"Het" is morpholinyl, wherein said morpholinyl is optionally substituted with one or more groups selected from C₁₋₃alkyl, halogen, cyano, methoxy, ethoxy, hydroxy, and amino; and

R⁴ is selected from -H and C₁₋₃alkyl.

12 A compound as claimed in claim 10

wherein R¹ is selected from cyclopentyl-methyl, cyclohexyl-methyl, cyclobutyl-

methyl, cyclopropyl-methyl, 4,4-difluorocyclohexyl-methyl, bicyclo[2.2.1]hept-5-en-2-ylmethyl, tetrahydropyranyl-methyl, tetrahydropyranyl-ethyl, tetrahydrofuranyl-methyl, morpholinyl-methyl, piperdinylethyl, N-methyl-piperdinylmethyl, and piperdinyl-methyl;

R^2 is selected from t-butyl, n-butyl, 2-methyl-2-butyl, isopentyl, 2-methoxy-2-propyl, 2-hydroxy-propyl, trifluoromethyl, 1,1-difluoroethyl, 2,2,2-trifluoroethyl, 1-methyl-propyl, 1,1-dimethyl-propyl, 1,1-dimethyl-3-butene-1-yl, ethyl, and 2-propyl;

5 "Het" is morpholinyl, wherein said morpholinyl is optionally substituted with one or more C_{1-3} alkyl; and

R^4 is selected from -H and methyl.

13. A compound as claimed in claim 10

wherein

10 R^1 is cyclohexyl-methyl, cyclobutyl-methyl, cyclopropyl-methyl, 4,4-difluorocyclohexanemethyl, N-methylpiperidine-2-yl methyl, and tetrahydropyranyl-methyl;

R^2 is t-butyl and 1,1-difluoroethyl;

15 "Het" is morpholinyl, wherein said morpholinyl is optionally substituted with one or more C_{1-3} alkyl; and

R^4 is selected from -H and methyl.

14. A compound according to any one of claims 1-13 for use as a medicament.

20 15. The use of a compound according to any one of claims 1-13 in the manufacture of a medicament for the therapy of pain.

16. The use of a compound according to any one of claims 1-13 in the manufacture of a medicament for the treatment of anxiety disorders.

25


17. The use of a compound according to any one of claims 1-13 in the manufacture of a medicament for the treatment of cancer, multiple sclerosis, Parkinson's disease, cancer, Huntington's chorea, Alzheimer's disease, gastrointestinal disorders and cardiovascular disorders.

30

18. A pharmaceutical composition comprising a compound according to any one of claims 1-13 and a pharmaceutically acceptable carrier.


19. A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-13.

5 20. A method for preparing a compound of Formula I,



comprising:

reacting a compound of Formula II,



10

with a compound of R^2COX , in the presence of a base, such as an alkylamine, and optionally a coupling reagent, followed by treatment with an acid; wherein

15 X is selected from Cl, Br, F and OH;

R^1 is selected from $\text{C}_{1-10}\text{alkyl}$, $\text{C}_{2-10}\text{alkenyl}$, $\text{C}_{3-10}\text{cycloalkyl-C}_{1-4}\text{alkyl}$, $\text{C}_{4-8}\text{cycloalkenyl-C}_{1-4}\text{alkyl}$, $\text{C}_{3-6}\text{heterocycloalkyl-C}_{1-4}\text{alkyl}$, $\text{C}_{3-10}\text{cycloalkyl}$, $\text{C}_{4-8}\text{cycloalkenyl}$, and $\text{C}_{3-6}\text{heterocycloalkyl}$, wherein said $\text{C}_{1-10}\text{alkyl}$, $\text{C}_{2-10}\text{alkenyl}$, $\text{C}_{3-10}\text{cycloalkyl-C}_{1-4}\text{alkyl}$, $\text{C}_{4-8}\text{cycloalkenyl-C}_{1-4}\text{alkyl}$, $\text{C}_{3-6}\text{heterocycloalkyl-C}_{1-4}\text{alkyl}$,

20 $\text{C}_{3-10}\text{cycloalkyl}$, $\text{C}_{4-8}\text{cycloalkenyl}$, and $\text{C}_{3-6}\text{heterocycloalkyl}$ used in defining R^1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, $\text{C}_{1-6}\text{alkylamino}$ and $\text{diC}_{1-6}\text{alkylamino}$;


25 R^2 is selected from $\text{C}_{1-10}\text{alkyl}$, $\text{C}_{2-10}\text{alkenyl}$, $\text{C}_{3-10}\text{cycloalkyl}$, $\text{C}_{3-10}\text{cycloalkyl-C}_{1-4}\text{alkyl}$, and $\text{C}_{4-8}\text{cycloalkenyl-C}_{1-4}\text{alkyl}$, wherein said $\text{C}_{1-10}\text{alkyl}$, $\text{C}_{2-10}\text{alkenyl}$, $\text{C}_{3-10}\text{cycloalkyl}$, $\text{C}_{3-10}\text{cycloalkyl-C}_{1-4}\text{alkyl}$, and $\text{C}_{4-8}\text{cycloalkenyl-C}_{1-4}\text{alkyl}$ used in

defining R² is optionally substituted by one or more groups selected from halogen, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C₁₋₆alkylamino and diC₁₋₆alkylamino;

R³ is selected from -H, C₁₋₆alkyl and C₁₋₆acyl optionally substituted with one or more groups selected from CH₃C(=O)-O-, halogen, cyano, methoxy, ethoxy, hydroxy, amino, alkylamino, dialkylamino, and C₃₋₆heterocycloalkyl; and R⁴ is selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, and C₃₋₆cycloalkyl-C₁₋₄alkyl.

10 21. A compound of 2-Bromo-N-(4-{[[2-tert-butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl](methyl)amino]sulfonyl}phenyl)acetamide.


22. A method for preparing a compound of Formula IA,



15 IA

comprising:

reacting a compound of Formula IIA,



IIA

20 with a compound of R²COX, in the presence of a base, such as an alkylamine, and optionally a coupling reagent, followed by treatment with an acid; wherein

X and X¹ are independently selected from Cl, Br, F and OH;
G is CH or N;
R¹ is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl,
C₄₋₈cycloalkenyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₁₀cycloalkyl,
5 C₄₋₈cycloalkenyl, and C₃₋₆heterocycloalkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, C₄₋₈cycloalkenyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, and C₃₋₆heterocycloalkyl used in defining R¹ is
optionally substituted by one or more groups selected from halogen, cyano, nitro,
methoxy, ethoxy, methyl, ethyl, hydroxy, CH₃C(=O)-O-, amino, C₁₋₆alkylamino and
10 diC₁₋₆alkylamino;

R² is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, and C₄₋₈cycloalkenyl-C₁₋₄alkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, and C₄₋₈cycloalkenyl-C₁₋₄alkyl used in
15 defining R² is optionally substituted by one or more groups selected from halogen, C₃₋₅heteroaryl, methoxy, ethoxy, methyl, ethyl, hydroxy, amino, C₁₋₆alkylamino and diC₁₋₆alkylamino;

R³ and R^{3a} are independently selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkyl-O-C(=O)-, C₁₋₆alkyl-HN-C(=O)-, H₂N-C(=O)-, and C₁₋₆acyl, wherein said C₁₋₆alkyl, C₂₋₆alkenyl, and C₁₋₆acyl used in defining R³ is optionally substituted with one
20 or more groups selected from CH₃C(=O)-O-, halogen, cyano, methoxy, ethoxy, hydroxy, amino, C₁₋₆alkylamino, diC₁₋₆alkylamino, and C₃₋₆heterocycloalkyl; and

R⁴ is selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, and C₃₋₆cycloalkyl-C₁₋₄alkyl.